Ten‐year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus

作者：Paolo Bidoli, Emilio Bajetta, Simonetta Chiara Stani, Daniela De Candis, Armando Santoro, Maurizio Valente, Roberto Zucali, Pinuccia Valagussa, Gianni Ravasi, Gianni Bonadonna · 发表于：Cancer · 年份：2002 · DOI：10.1002/cncr.10233 · 被引用次数：49 · 研究领域：Esophageal Cancer Research and Treatment、Head and Neck Cancer Studies、Esophageal and GI Pathology

BACKGROUND: The effects of multimodality treatment on the survival of patients with esophageal carcinoma are unclear. The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma. METHODS: Of 106 consecutive patients who were recruited between 1985 and 1992, 101 patients were evaluable. Cisplatin (100 mg/m2 per day) on Day 1 and fluorouracil (1000 mg/m2 per day) on Days 1-4 were given for two cycles, with concomitant RT (30 grays [Gy] in 15 fractions) over 19 days. Patients with potentially resectable tumors were then assessed for curative surgery; the other patients received two more courses of chemotherapy and further RT (20 Gy in 10 fractions). RESULTS: Of 40 patients who were candidates for surgery, 32 patients underwent surgery, and 24 patients had complete resection; 8 patients (25%) had no residual tumor in the specimen, and 12 patients (37%) had microscopic foci only. Surgical mortality was high (22%). Of 61 nonsurgical patients, 37 patients (61%) achieved complete clinical remission, and 14 patients (23%) achieved partial remission. The median survival for the entire series was 15 months (range, 1-136 months). The overall survival rate was 22% at 5 years and 12% at 10 years. At 10 years, freedom from disease progression was similar in the two groups (24%), whereas the median survival (22 months vs. 12 months) and the overall survival rates (17% vs. 9%) we...